The helicobacter eradication aspirin trial (HEAT): demographic data for randomised (H.pylori positive) patients

Stevenson, DJ, Dumbleton, JS, Avery, A , Coupland, C, Hobbs, F, Kendrick, D, Moore, MV, Rubin, GP, Smith, Murray and Hawkey, CJ (2018) The helicobacter eradication aspirin trial (HEAT): demographic data for randomised (H.pylori positive) patients. In: UEG Week, October 20-24, Vienna.

The helicobacter eradication aspirin trial (HEAT): demographic data for randomised (H.pylori positive) patients
[img] PDF
HEAT Poster (UEGW October 2018).pdf - Whole Document

Item Type:Conference or Workshop contribution (Poster)
Item Status:Live Archive


The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, double blind, randomised controlled trial investigating whether Helicobacter pylori eradication reduces the incidence of hospitalisation for peptic ulcer bleeding [1]. Participants are subjects aged over 60, taking low dose aspirin for at least four months at the time of recruitment; all participants were recruited from primary care. H. pylori positive participants were randomised to receive one week active trial treatment (lansoprazole 30mg, clarithromycin 500mg and metronidazole 400mg twice daily) or placebo. Recruitment to the trial started in 2012 and completed in 2017; follow-up is endpoint driven and is ongoing.

Participants are followed up using a bespoke web-based trial management system that communicates directly with HEAT Toolkit software downloaded at participating GP practices, which issues MIQUEST [2] queries searching follow-up criteria. The primary endpoint of the study is the rate of hospitalisation due to definite or probable peptic ulcer bleeding. The study will end when 87 adjudicated events have occurred. Events are tracked by accumulating information from MIQUEST searches of GP databases via the HEAT toolkit, patient contact, review of national secondary care admission and mortality data.

HEAT is being conducted in practices across the whole of the UK with 188,428 invitation letters sent from 1,208 GP practices. A total of 37,247 positive responses were received, representing a 20% response rate. Of those, 30,025 patients were consented to the study of whom 5,356 H. pylori positive patients were randomised. The percent of H. pylori positive patients varied from 13% to 39% throughout the country. Multiple deprivation scores applied to the data indicated an increase in response with less deprivation, but a decrease in the number of randomised patients.
The mean age at randomisation for all participants was 73.6 ± 7.0 (SD) years, and 73.8% of participants are male. Only 7.2% of participants are smokers although 52.9% are ex-smokers. A total of 15% of the randomised patients have withdrawn from the trial, and 100 patients have died so far.

The trial methodology has shown that recruitment of large numbers of patients from primary care is attainable, with the assistance of the NIHR Clinical Research Network, and could be applied to other outcomes studies at relatively low cost.
Last year, there were almost 17,000 hospital admissions for gastric ulcers [3] and more than 1,850 recorded deaths [4] for gastric and duodenal ulcers. If successful, the study will help to reduce NHS costs and improve health outcomes by reducing hospital admissions, increasing patient safety and preventing premature deaths.

Keywords:Clinical trial, Helicobacter pylori, Aspirin
Subjects:B Subjects allied to Medicine > B200 Pharmacology, Toxicology and Pharmacy
A Medicine and Dentistry > A300 Clinical Medicine
Divisions:College of Social Science > School of Health & Social Care
ID Code:33970
Deposited On:06 Nov 2018 13:44

Repository Staff Only: item control page